From The Motley Fool · Motley Fool Transcribing · · 2m
Abeona Therapeutics Q3 2026 Earnings Results
Abeona Therapeutics reports $13.5M ZEVASKYN revenue growth with 15 patients treated and ABO-801 acquisition for eosinophilic esophagitis.
In brief
Abeona Therapeutics reports $13.5M ZEVASKYN revenue growth with 15 patients treated and ABO-801 acquisition for eosinophilic esophagitis. Abeona Therapeutics reported $13.5 million in ZEVASKYN revenue for Q3 2026, treating 15 patients with a Phase III-ready drug candidate for eosinophilic esophagitis. Originally…
Q3 2026 Earnings Results
Abeona Therapeutics reported net revenue of $13.5 million, an 18% increase compared with the prior quarter.
Patient Treatments
Six patients were treated with ZEVASKYN in the third quarter, bringing the total number of patients treated since launch to 15.
Qualified Treatment Centers
Eight total sites are now activated in the ZEVASKYN network following the addition of Cincinnati Children's and University of Florida Health.
Operational Milestones
Four centers now have first-hand ZEVASKYN treatment experience after the Children's Hospital of Philadelphia and the University of Texas Medical Branch completed their first treatments.
Manufacturing Performance
One lot out of 15 total treated since launch was out of specifications for the pan-CK identity assay, preventing revenue recognition for that specific treatment.
Net Loss
Net loss of $4.8 million or $0.08 per share, compared with a net loss of $20.2 million or $0.35 per share in the second quarter.
Research and Development Expenses
Research and development expenses decreased to $3.7 million from $5 million in the prior quarter.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased to $17.1 million from $15.8 million in the second quarter.
Cash Position
Cash position stands at $134.9 million as of September 30, 2026.
Acquisition of ABO-801
Abeona issued $20 million in common stock to Ellodi Pharmaceuticals for the Phase III-ready orphan drug candidate ABO-801.
Development Milestones
Up to $30 million is payable upon FDA approval of ABO-801, with additional $30 million tied to commercial milestones.
Royalties
Low to mid-teens tiered royalties are eligible to be paid to Ellodi on net sales of ABO-801.
PIPE Financing
$30 million in gross proceeds from a private placement was announced to fund pipeline development and ZEVASKYN commercialization.
Eosinophilic Esophagitis Prevalence
360,000 diagnosed patients in the U.S. represent the target market for the ABO-801 program.
Peak Revenue Potential
Greater than $750 million in annual sales is estimated for ABO-801 due to growing disease prevalence.
ABO-801 Development Costs
$50 million to $60 million is the estimated clinical cost to bring the candidate through to FDA approval.
What to remember
Abeona Therapeutics reported $13.5 million in ZEVASKYN revenue for Q3 2026, treating 15 patients with a Phase III-ready drug candidate for eosinophilic esophagitis.
